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Abstract
In the field of organ transplantation, donor-specific anti-HLA antibodies (DSA) have 
gained more popularity, as antibody-mediated rejection (AMR) has been recognized 
as an important factor to determine allograft survival. Thus, it is reasonable to believe 
that appropriate control of DSA is directly linked to well-managed immunosuppression, 
resulting in free from AMR. First, in order to prevent and manage AMR, it is of vital 
importance to be familiar with updated knowledge regarding crossmatch test and DSA 
detection methods, including intra-graft DSA. Second, it is also crucial to understand 
the standard criteria to diagnose AMR. Although pathological diagnosis and serum 
DSA (s-DSA) detection play the central role, the recent trend seems to be detection of 
intra-graft DSA (g-DSA). Third, regarding organ transplantation between sensitized 
pairs, the acceptable outcomes are obtained owing to recent preoperative desensitization 
protocols: depletion/modification of B cells, apheresis for antibodies, and inhibition of 
reaction between DSA and HLA. Finally, we would like to discuss the treatment of AMR. 
Further advances in diagnosis methods and emergences of effective treatments would be 
expected for acceptable control of AMR. In this chapter, we will review from the basics to 
recent topics in order to understand DSA and AMR.
Keywords: organ transplantation, antibody-mediated rejection, donor-specific  
anti-HLA antibodies, intra-graft donor-specific anti-HLA antibodies, immunocomplex 
capture fluorescence analysis
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1. Introduction
Recent advances in immunosuppression permit for organ transplantation between sensitized 
recipients and donors with acceptable outcomes. However, it is true that the management 
of acute or, in particular, chronic antibody-mediated rejection (AMR) due to donor-specific 
anti-HLA antibodies (DSA) is still a crucial issue to improve long-term graft survival. Because 
chronic changes of AMR are irreversible, it is also true that an early accurate diagnosis of AMR 
is required to prevent severe consequences. Thus, it is reasonable to believe that DSA is a main 
research topic to improve the outcome of organ transplantation. In the 1960s, the introduction 
of azathioprine brought the beginning of contemporary organ transplantation [1]. Following 
this era, incompatibilities, anti-AB [2, 3] and anti-HLA antibodies [4], were recognized as a 
crucial barrier for organ transplantation. In the next half-century, the main attention was paid 
to cellular rejection: T-cell-mediated rejection [5]. This resulted in the development of calci-
neurin inhibitors [6] and several antibody drugs [7]: a depletion of lymphocytes that enabled 
the control of T-cell-mediated rejection. However, AMR remains an important issue that is 
still not addressed. Then, DSA have finally received strong attention in the twenty-first cen-
tury because DSA are important factors to determine long-term graft survival. In this chapter, 
we will review DSA in organ transplantation and discuss effectiveness of a novel application 
of immunocomplex capture fluorescence analysis (ICFA), as well as crossmatch examinations, 
protocols of desensitization, and outcomes of crossmatch positive organ transplantation.
2. Assessment for donor-specific anti-HLA antibodies
To assess reactive DSA in recipient serum, a crossmatch test or measurement of DSA is per-
formed routinely in clinical organ transplantation. There are several crossmatch methods: 
lymphocyte cytotoxic test (LCT), flow cytometry crossmatch (FCXM), and ICFA. In addition 
to crossmatch test, antibody detection methods such as flow PRA screening and single anti-
gen bead assay (SAB) are utilized in clinical settings. Generally, it is important to understand 
the advantages and disadvantages of these methods and interpret appropriately.
2.1. Lymphocyte cytotoxic test
Antigen–antibody and complement-dependent reactions are observed in this traditional 
direct-crossmatch test. Donor lymphocytes are incubated in the recipient serum, followed by 
the addition of complements. Under the circumstances where there are DSA in the recipient 
serum, lymphocytes are necrotized by the complement-dependent cytotoxicity reaction. Then, 
adding eosin dye, the ratio of necrotized lymphocytes is counted by a phase-contrast micros-
copy (Figure 1). The disadvantages of LCT are relatively low sensitivity, difficulty in obtaining 
donor alive lymphocytes, and subjective judges. Furthermore, it should be noted that some-
times non-DSA reaction can be observed. Conversely, only this traditional method is capable 
of visualizing real reactions against donor cells, including non-DSA reactions [8]. Thus, it is 
true that careful attention should be paid when positive reaction in LCT is detected [9].
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2.2. Flow cytometry crossmatch
FCXM is an examination that flow cytometry technology is applied. As characteristics of 
FCXM test, sensitivity is high enough to detect a slight amount of DSA. Therefore, it should 
be paid attention that non-HLA antibodies might be detected: false positive. Because of high-
sensitivity examination, rigorous quality control is required. To apply FCXM, donor lympho-
cytes and recipient serum samples were utilized. Subsequently, antihuman IgG antibodies are 
added and positivity is determined [10]. In addition, to add CD3 or CD19, T cells and B cells 
can be separated and analyzed simultaneously (Figure 2).
2.3. Immunocomplex capture fluorescence analysis
WAKFlow HLA antibody class I and II ICFA (Wakunaga Pharmaceutical Co., Ltd., Osaka, 
Japan) is one of the crossmatch tests by using donor lymphocytes and recipient serum [11]. 
This technique can detect DSA immunocomplex with high specificity [12]. As a detection 
system, Luminex xMAP technology (Luminex Corporation, Austin, TX) is applied. Schematic 
presentation of ICFA is shown in Figure 3. First, HLA and DSA complexes are formed follow-
ing the reaction between donor lymphocytes and recipient serum containing DSA. Second, 
lymphocytes are lysed and complexes remain in lysates. Third, these complexes are captured 
by anti-HLA monoclonal antibodies fixed on Luminex beads, and subsequently PE-conjugated 
human anti-IgG is added. Finally, Luminex system detects these PE-conjugated anti-human 
Figure 1. Lymphocyte cytotoxicity test (LCT). (a) Schematic presentation of LCT. (b) Representative results of 
LCT. Necrotized lymphocytes were stained in black by eosin dye. Negative reaction (grade 1–2) and positive reaction 
(grade 4–8).
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IgG signals. As ICFA characteristics, the following features are noted: (1) the specificity of 
identifying HLA antibodies is high, and (2) class I and II antibodies can be identified sepa-
rately. Furthermore, in terms of recent advances in ICFA, DR, DQ, and DP, DSA can be identi-
fied separately.
2.4. FlowPRA screening
To identify anti-HLA antibodies in serum, FlowPRA screening test is performed. First, a reac-
tion is caused between anti-HLA antibodies and latex beads coated with HLA antigens. Then, 
Figure 2. Flow cytometry crossmatch (FCXM). (a) Schematic presentation of FCXM. (b) an example of positive reaction 
by non-HLA antibodies. (c), (d) representative results of FCXM using T cell (c) or B cell (d).
Figure 3. Schematic presentation of immunocomplex capture fluorescence analysis (ICFA).
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FITC-conjugated antihuman IgG is added. Subsequently, mean fluorescence intensity (MFI) 
and shift from negative control are calculated based on flow cytometry analyses (Figure 4). 
Each mixed class I and II HLA antigen is separately coated on latex beads, derived from about 
30 types of panel cells [13]. Depending on the human race, there is a possibility that rare HLA 
Figure 4. FlowPRA screening. (a) Schematic presentation of FlowPRA screening. (b) Examples of positive FlowPRA 
screening results about class I (upper) and class II (lower).
Figure 5. Schematic presentation of single antigen bead assay (SAB).
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antigens are not covered. These disadvantages should be recognized. Generally, if a positive 
reaction would be observed, the following SAB is applied to identify the specificity of anti-
HLA antibodies.
2.5. Single antigen bead assay
To identify the specificity of anti-HLA antibodies, SAB is performed when crossmatch test 
and/or FlowPRA is positive. First, a reaction is observed between anti-HLA antibodies 
and Luminex beads coated with a single HLA antigen extracted from gene-modified cells. 
Following steps are similar to those of FCXM. Finally, these reactions, MFI of PE signals, were 
calculated by Luminex system (Luminex Corporation). According to HLA typing of donor, 
the presence of DSA is judged. It is often used in LABScreen single antigen HLA class I/II 
beads: LABScreen single antigen class I/LABScreen single antigen class II (One Lambda Inc., 
Canoga Park, CA) or WAKFlow HLA antibody class I HR and WAKFlow HLA antibody class 
II HR (Wakunaga Pharmaceutical Co., Ltd) (Figure 5). As an important point, because these 
single HLA antigen beads do not include all types of HLA antigens, we should be familiar 
with SAB kit to judge the existence of DSA appropriately.
3. Assessment for intra-graft donor-specific anti-HLA antibodies
Due to recent advances in examinations for DSA, the assessment for g-DSA has been paid atten-
tion. In fact, it is hard to understand that s-DSA damage allografts without localization in target 
organs. Thus, hereafter, the assessment of g-DSA would gain more popularity as diagnosis or 
prognosis factors. Although the presence of g-DSA is not included in AMR diagnosis criteria 
currently, g-DSA might be a key criterion for considering AMR in the near future. It would be 
better that clinicians and researchers are aware of this novel topic. Here, we will present rep-
resentative two different methods. We will also delve into graft ICFA technique in this section.
3.1. Dissociation between HLA and DSA (acid elution method)
To obtain free DSA from allografts, dissociation HLA and DSA complexes are attempted. 
So far, g-DSA detection in the kidney [14–16], liver [17], and lung [18] were reported. This 
method requires the following steps: (1) Wash more than seven times to prevent from detec-
tion s-DSA incorrectly. (2) Dissociate these complexes by acid (buffer). (3) Detect dissociated 
DSA by SAB (Figure 6). As compared to graft ICFA, mentioned later, acid elution method 
has weak points regarding simplicity and remains doubtful points whether DSA denature 
or not during the acid elution step. However, SAB analysis following acid elution seems to 
be accepted widely and allows to identify specific DSA even where multiple candidate DSA 
exist. The common recognition of g-DSA assessment seems to be that g-DSA is an important 
factor to determine graft survival and more sensitive than s-DSA [14].
3.2. Graft immunocomplex capture fluorescence analysis (non-dissociation 
technique)
WAKFlow HLA antibody class I and II ICFA is an attractive tool to identify HLA/DSA com-
plexes as mentioned above, by means of WAKFlow HLA antibody class I and II (Wakunaga 
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Pharmaceutical). It is not only for serum of recipients but also for allograft specimens. The 
first graft ICFA was introduced as an effective tool for detection of g-DSA in 2017 [19, 20]. 
Graft ICFA can be performed as previously described by Nakamura et al. Graft samples were 
obtained by means of a percutaneous needle biopsy. To standardize the results of graft ICFA, 
2 mm specimen was used for each analysis. Regarding graft ICFA to identify HLA expres-
sion, samples were washed enough in PBS. As compared to acid elution method of DSA from 
grafts associated to g-DSA detection by SAB, graft ICFA does not allow to identify individual 
responsible HLA alleles, such as HLA-A24, etc. However, in the setting of real organ trans-
plantation, generally HLA alleles are identified prior to transplantation. Thus, it does not 
seem to be difficult to narrow down candidate HLA. It is true, therefore, that current graft 
ICFA is clinically useful to diagnose AMR. Moreover, the combination of acid elution method 
and graft ICFA allows to obtain useful information regarding g-DSA. Further advances in 
graft ICFA would be expected.
(Ethics Committee approval was obtained from the internal research ethics committee of Kyoto 
Prefectural University of Medicine. The clinical trial registration number is UMIN000023787.)
3.3. Data interpretation
MFI of samples was calculated by the Luminex system. A ratio of sample MFI/blank beads 
MFI of all negative samples, including HLA matched recipients’ samples, + 2SD is demon-
strated below 0.9 (data not shown) (please refer to [19, 20]). Then the ratio was determined, 
and ≥ 1.0 was considered as a positive result. Furthermore, to compensate baseline reaction, 
the following index was also calculated. Index = (XHLA-(NHLA-NBB)XBB/NBB)/XBB: XHLA, sample 
Figure 6. The flowchart of the acid elution method (dissociation technique).
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MFI; XBB, sample blank beads MFI; NHLA, the mean MFI of negative samples; and NBB, the mean blank beads MFI of negative samples. Given the results of negative samples, the index 
≥1.5 was considered as a positive result.
3.4. DSA-HLA complexes in the liver, heart, lungs, pancreas, and small intestine are 
also successfully detected by graft ICFA
To confirm whether graft ICFA can be applied to other organs besides the kidney [19, 20], 
we employed ten liver transplant recipients and a liver transplant recipient who underwent 
autopsy due to primary graft dysfunction. Samples of other possible organs such as the heart, 
lung, pancreas, and small intestine from this patient were pretreated according to the graft ICFA 
preparation method. Contaminated blood cells in samples were minimum, confirmed by his-
tology. Luminex analyses detected PE signals from the positive control samples in all organs. 
Thus, it can be concluded that graft ICFA can be applied for all organ transplantation (Figure 7).
3.5. Sensitivity and specificity of graft ICFA to determine pathological AMR in renal 
transplantation
In order to prove a hypothesis—graft ICFA is useful to detect g-DSA and AMR—a total of 
40 Japanese renal transplant recipients were included prospectively. They underwent graft 
biopsy and were examined by graft ICFA as previously described [19, 20]. According to the 
results of graft ICFA, these patients were divided into the g-DSA+ and g-DSA- groups to assess 
Figure 7. Intra-graft DSA (g-DSA) in all possible allografts can be analyzed by graft ICFA.
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the sensitivity and specificity of graft ICFA to predict pathological AMR. In the current study, 
this technique has demonstrated 100% sensitivity (12/12) and 92.9% specificity (26/28). Thus, 
it is reasonable to believe that positive graft ICFA results strongly suggest the onset of AMR.
4. Diagnosis of antibody-mediated rejection
4.1. Renal transplantation
With renal allograft dysfunction, it can be diagnosed as AMR, provided that C4d deposited 
in peritubular capillaries (ptc) and antibodies or complement deposition are confirmed in 
vascular fibrinoid necrosis, in addition to s-DSA detection. Recently, AMR can be diagnosed 
according to the Banff classification 2015 [21].
Acute AMR:
The following three criteria should be met when acute AMR is diagnosed:
1. Histological features of acute tissue injury, including at least one of the following
• Microvascular inflammation g > 0 (excluding recurrent or de novo glomerulonephritis), 
ptc > 0, or v > 0 (intimal/transmural arteritis).
• Acute thrombotic microangiopathy (without any other apparent reasons).
• Acute tubular injury (without any other apparent reasons).
2. Histological features due to DSA and vascular endothelium reaction
• Linear C4d deposition in ptc (C4d2 or C4d3 (frozen sections)/C4d > 0 (paraffin embed-
ded sections))
• Moderate microvascular inflammation g + ptc ≥ 2.
• Detection of genetic transcript expression in biopsy specimens due to endothelial injury.
3. Detection of s-DSA
Chronic AMR:
The following three criteria have to be met:
1. Histological features of chronic tissue injury, including at least one of the following
• Transplant glomerulopathy (cg > 0), in the case of no chronic thrombotic microangiopa-
thy, includes histologic features detected by electron microscope (EM).
• Severe ptc basement membrane multilayering by EM.
• New onset of arterial intimal fibrosis (without any other apparent reasons).
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2. Histological features due to DSA and vascular endothelium reaction
• Linear C4d deposition in PTC (C4d2 or C4d3(frozen sections)/C4d > 0 (paraffin embed-
ded sections))
• Moderate microvascular inflammation g + ptc ≥ 2.
• Detection of genetic transcript expression in biopsy specimens due to endothelial injury.
3. Detection of serum DSA
Figure 8. Histopathological impacts of g-DSA presence. A. The Banff histologic scores are analyzed individually based 
on the g-DSA status: G-DSA- or g-DSA+. B. The Banff histologic scores based on the g-DSA status: G-DSA- or g-DSA+ 
without ABO-incompatible cases. C. These items are reanalyzed depending on g-DSA values: G-DSA-, g-DSA < 10, and 
g-DSA ≥ 10, including ABO-incompatible cases. ****p < 0.0001, ***p < 0.0005, **p < 0.005, and *p < 0.05.
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4.1.1. The presence of g-DSA (graft ICFA) is associated with microvascular lesions in renal 
transplantation
To confirm the consistency of graft ICFA results, the individual scores of the Banff classifi-
cation were analyzed between g-DSA- and g-DSA+ renal transplant recipients (g-DSA+ 15, 
g-DSA- 25 recipients). As a result, individual g, cg, ptc, and ptc-bm scores were significantly 
higher in g-DSA+ patients. Interestingly, there was no apparent difference in the C4d stain-
ing score, primarily due to the presence of ABO-incompatible cases in both groups (32.0% 
and 33.3% in the g-DSA- and + groups, respectively) (Figure 8A). Thus, ABO-incompatible 
cases were removed from both groups. Then, the C4d result showed that 0.45 ± 0.17 and 
1.73 ± 0.33 in the g-DSA- and g-DSA+ groups, respectively (p = 0.0184) (Figure 8B). Next, 
g-DSA+ patients were divided into low g-DSA group, g-DSA+ < 10, and high g-DSA group, 
g-DSA+ ≥ 10. Then, this result demonstrated that g and ptc deteriorated in g-DSA concentra-
tion manner. In contrast, only g-DSA+ ≥ 10 group showed significant higher scores in cg, 
mm, ptc-bm, and C4d (Figure 8C). These results might indicate that g-DSA causes microcir-
culation lesions and high g-DSA means chronic allograft damages. To correspond to a recent 
functional concept, g + ptc (microvascular inflammation), g + cg + ptc (microvascular lesions), 
and cg + mm (microvascular deterioration), we also analyzed these scores again. Expectedly, 
g + ptc and g + cg + ptc deteriorated stepwise according to g-DSA scores, but cg + mm referring 
chronic lesions is clearly higher only in the g-DSA ≥ 10 group (Figure 9). It is true, therefore, 
that g-DSA assessment by graft ICFA accurately supports the diagnosis of AMR.
4.2. Liver transplantation
Generally, it is often discussed that liver allografts tend to be resistant against AMR due to 
Kupffer cell DSA clearance, HLA expression in microvasculature, allografts size, and regen-
erative capacity of the liver. Diagnosis criteria are suggested in the Banff meeting [22].
Define acute AMR:
The following four criteria should be met to diagnose acute AMR:
1. Histological features of acute tissue injury, including at least one of the following
Portal microvascular endothelial cell hypertrophy, eosinophilic and neutrophilic portal 
microvasculitis, portal edema, and ductular reaction; cholestasis is usually present but 
variable; edema and periportal hepatocyte necrosis, active lymphocytic, and/or necrotiz-
ing arteritis.
2. Positive s-DSA.
3. Diffuse microvascular C4d staining (C4d = 3).
4. Excluding other lesions possibly mimic AMR.
Suspicious for AMR (both criteria required).
Serum DSA + and positive histopathology score (h-score) (C4d + h-score ≥ 3).
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Indeterminate for AMR:
1. C4d + h-score ≥ 2.
2. DSA and C4d immunohistochemistry not available and not apparent.
3. Coexisting pathophysiology might cause similar injury.
Liver allograft chronic active AMR is also considered as an important factor for determining 
long-term outcome [23, 24]. Chronic active AMR is diagnosed when the condition meets the 
all following criteria:
1. Histologic features consistent with chronic active AMR. (a) At least mild mononuclear por-
tal and/or perivenular inflammation with interface and/or perivenular necroinflammatory 
activity. (b) At least portal/periportal, sinusoidal, and/or perivenular fibrosis.
Figure 9. G-DSA effects on the functional clusters of the Banff classification. The functional clusters, g + ptc (microvascular 
inflammation), g + cg + ptc (microvascular lesions), and cg + mm (microvascular deterioration), are analyzed according 
to the presence or absence of g-DSA (A) and g-DSA values: G-DSA-, g-DSA < 10, and g-DSA ≥ 10 (B). ****p < 0.0001 and 
*p < 0.05.
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2. Detection of serum DSA.
3. Focal C4d deposition in portal tract microvascular endothelia (> 10%).
4. Other lesions can be denied.
4.3. Heart transplantation
Following heart transplantation, the onset of AMR is generally estimated around 10–20% 
[25]. In the field of heart transplantation, AMR is also considered as an important prognosis 
factor. In fact, the consequences are severe, and the development of cardiac allograft vas-
culopathy (CAV) has a huge impact. As with other organ transplantations, timing of AMR 
onset is diverse: both acute AMR within 1 week after transplantation and chronic AMR in 
the remote period can be seen. Again, allograft biopsy also plays a crucial role to accurately 
diagnose AMR. Repeated allograft biopsies seem to be required for achieving good long-term 
outcomes. Interestingly, regarding de novo DSA synthesized after 2 months following heart 
transplantation, class II DSA are dominant [25].
Diagnosis criteria of heart allograft AMR were discussed in the international society for heart 
and lung transplantation working formulation consensus [26]. First of all, substrates were 
divided into two categories: histologic investigations (H) and immunopathologic studies 
(I). Histologic features of heart AMR are as follows: activated mononuclear cell infiltration, 
interstitial edema, hemorrhage, necrosis, and vascular thrombosis. On the other hand, C4d, 
CD68 (paraffin section), C4d, or C3d (frozen section) are considered mandatory panels of 
immunopathologic studies. Furthermore, CD3, CD20, C3d, endothelial cell CD31 or CD34, 
complement regulatory proteins (paraffin section), and fibrin and immunoglobulin G/M (fro-
zen section) are regarded as secondary or optional panels. In total, the current report of AMR 
in heart is noted from Grade 0 to 3 as follows:
pAMR 0: negative for pathologic AMR (H0/I0)
pAMR 1(H+): histopathologic AMR (H+/I−)
pAMR 1 (I+): immunopathologic AMR (H−/I+)
pAMR 2: pathologic AMR (H+/I+)
pAMR 3: severe AMR (interstitial hemorrhage, capillary fragmentation, mixed inflammatory 
cell infiltration, endothelial cell pyknosis and/or karyorrhexis, and marked edema and I+)
pAMR 3 cases usually demonstrate severe hemodynamic dysfunction and poor consequences.
Scoring system of criteria for pathologic diagnosis of cardiac AMR is slightly different between 
immunohistochemistry and immunofluorescence analyses. These criteria are summarized in 
Table 1.
4.4. Lung transplantation
Regarding AMR following lung transplantation, the main reason is also DSA, although 
a role of non-HLA antibodies was also described [27]. Hachem et al. [28] have reported, 
in 2010, a prospective study on AMR after lung transplantation, which deepened our 
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understanding of clinical AMR managements. In 2016, a consensus statement has been 
proposed from the international society for heart and lung transplantation [29].
Lung allograft AMR can be divided into clinical and subclinical AMR, depending on whether 
there is allograft dysfunction or not. Next, as similar to other organs, these clinical and sub-
clinical AMR are subcategorized as define, probable, or possible. To determine certainty of 
clinical AMR, the following five criteria are proposed: allograft dysfunction, other causes 
excluded, lung histology, lung biopsy C4d, and s-DSA. Define lung AMR is determined by 
positive for all five criteria. In case anyone of them is negative, it is considered as probable 
AMR, excluding allograft dysfunction (Table 2). There are histopathologic features of AMR, 
including the following—neutrophil margination, neutrophil capillaritis/arteritis without any 
signs of pneumonia, or other apparent reasons—though these features are not specific for lung 
AMR. In terms of lung histology, further advancement and organization would be required.
4.5. Small bowel transplantation
Due to recent increased recognition of AMR, AMR is also considered as a serious issue in the 
small bowel transplantation field. However, the define diagnosis criteria have not been estab-
lished in the small bowel transplantation yet. There are few series of case reports in terms of 
intestine AMR. Although common understandings of AMR also seem to be C4d deposition, 
capillaritis, and s-DSA positivity [30], there is a report which did not find clinical evidence 
between C4d positivity and the onset of AMR [31]. The establishment of diagnostic criteria 
should be required to standardize and manage AMR in intestine transplantation. The future 
contribution of g-DSA assessment would be also expected in this field.
Immunohistochemistry scoring system Immunofluorescence scoring system
Capillary C4d 
distribution
0 < 10% Negative Capillary C4d/
C3d distribution
0 < 10% Negative
1 10–50% Focal 1 10–50% Focal
2 > 50% multifocal/
diffuse
2 > 50% Multifocal/diffuse
Capillary C4d 
intensity
0 Negative/equivocal Capillary C4d/
C3d intensity
0 Negative/equivocal
1 Faint positive 1 Faint positive = 0–1+
2 Strong positive 2 Strong positive = 2–3+
Intravascular 
CD68 
distribution
0 < 10% Negative HLA-DR 
distribution
0 < 10% Negative
1 10–50% Focal 1 10–50% Focal
2 > 50% Multifocal/
diffuse
2 > 50% Multifocal/diffuse
HLA-DR intensity 0 Negative/equivocal
1 Faint positive = 0–1+
2 Strong positive = 2–3+
Table 1. Immunohistochemistry and immunofluorescence scoring system in heart AMR.
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5. Preoperative desensitization
To perform organ transplantation between a sensitized recipient and donor pair, preoperative 
desensitization is required. Generally, crossmatch positive organ transplantation is mainly 
performed in kidney and liver transplantation. Desensitization can be divided into three main 
treatments: depletion/modification of B cells, apheresis for antibodies, and inhibition of reac-
tion between DSA and HLA. The golden standard of B-cell depletion therapy is rituximab 
(anti-CD20 antibodies) administration [32–35]. There are a wide variety of rituximab admin-
istration protocols in terms of a dosage and schedule. In our institution, generally, rituximab 
(375 mg/m2) is administered in 2 weeks prior to organ transplantation [20]. Subsequent B-cell 
count in the peripheral blood is measured by flow cytometry. In addition to rituximab, to 
deplete B cells, anti-CD52 antibodies (alemtuzumab) also can be used, because higher than 
95% B cells express CD52 on the cell surface [36]. It has been reported that alemtuzumab-
combined regimens are safe and effective for highly sensitized recipients [36, 37]. Other anti-
bodies’ introduction would be expected regarding induction regimens.
To decrease DSA production and reaction, the importance of intravenous immune globulin 
(IVIG) has been reported. IVIG infusion significantly decreased the baseline flowPRA levels 
[38]. There is a variety of reports regarding the dosage and duration of IVIG (100 mg/kg/
day–4 g/kg/day, etc.), partially due to the cost problems.
Regarding apheresis therapy, double filtration plasmapheresis (DFPP) or plasma exchange 
(PE) is generally performed. Usually, as an index of DSA titer, MFI has gained its popularity. 
Given the fact of g-DSA and s-DSA assessments, DSA with MFI < 2500 might not deposit and 
cause clinical damages to allografts. Thus, although it depends on each institution, accept-
able DSA MFI prior to surgery might be estimated around 2000 [20] in renal transplanta-
tion. However, on the other hand, intensive posttransplant desensitization also can result in 
Allograft dysfunction Other causes 
excluded
Lung histology compatible with 
AMR
C4d s-DSA
Define + + + + +
Probable* + + + − +
+ − + + +
+ + − + +
+ + + + −
Possible + − − + +
+ + − − +
+ + + − −
+ − + − +
+ − + + −
+ + − + −
There is growing evidence that C4d negative AMR exists. Thus, the second line * cases are considered as an independent 
group.
Table 2. Lung AMR diagnosis criteria.
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comparable outcomes with non-sensitized transplantation [39]. For highly sensitized recipi-
ents, a phased desensitization protocol by using rituximab and bortezomib was advocated 
[34]. In fact, it is true that rituximab administration can deplete B cells but not plasma cells. 
Thus, it is reasonable to believe that rituximab and bortezomib combination therapy eradi-
cates the B-cell linage which is potentially associated with AMR.
Furthermore, the idea only relying on MFI might be unrefined. In other words, the quality of 
DSA is also important to determine the impact of DSA. Regarding the quality, IgG subclasses 
[1–4, 40] and complement fixing ability [41] seem to be paid attention, considering the severity 
of subsequent AMR and graft survival.
On the other hand, in liver transplantation, there seems to be no concrete evidence regarding 
DSA MFI just prior to transplantation. A large amount of hemorrhage during surgery and liver 
allograft resistance against DSA, etc., might complicate to set a MFI threshold. Nevertheless, 
Yoshizawa et al. [42] reported that class I DSA MFI > 10,000 has a negative impact on graft 
survival. Thus, it is important to keep circumstances where allograft injury due to remnant 
DSA is minimum and additional DSA production inhibited.
6. Treatment for antibody-mediated rejection
In other words, this is a treatment for B cells/plasma cells and DSA and reaction between DSA 
and HLA. Both for acute AMR and chronic active AMR, generally clinical managements also 
can be divided into medications and apheresis: steroid pulse, IVIG, Rituximab, etc., and DFPP 
or PE. In severe cases, it is true that splenectomy has a certain effect on AMR [43]. Regarding 
treatment for acute AMR, the concepts are the same: depletion of B cells, reduction of DSA, 
and inhibition of reaction between DSA and HLA. The core agents and methods are sum-
marized in Table. It is true that high-dose steroid administration is effective on all aspects of 
AMR treatment. There is no fixed data to determine the dosage and duration of steroid pulse 
therapy. However, generally, 10–100 mg/kg/day equivalent dosage of hydrocorticoid is admin-
istered as steroid pulse therapy, depending on the severity of AMR. For depletion of B cells, 
rituximab, alemtuzumab, or splenectomy is utilized. To reduce DSA, DFPP, or PE, apheresis 
methods are commonly used in the same way as desensitization. As immunomodulation, IVIG 
administration also plays an important role in controlling acute AMR. Given the fact of AMR 
pathogenesis, complement activation should be paid attention. Final tissue injury due to AMR 
would occur following activation of antibody-induced terminal complement cascade. Albeit 
limited evidence, it has been reported that eculizumab C5 inhibitor is effective to rescue an 
AMR allograft [44–47].
Recently, chronic active AMR has been paid strong attention, because this pathologic con-
dition directly deteriorates the long-term graft survival. Despite the recognition of chronic 
active AMR, diagnostic criteria are only established in kidney [21] and liver transplantation 
[22]. There seems to be no therapeutic consensus on this condition. Furthermore, it has gen-
erally resistance to ordinal AMR managements discussed above [48–50], although limited 
effectiveness was observed in few studies [51, 52]. Bachelet et al. [50] reported a treatment for 
chronic active AMR (mean eGFR 30.6 mL/min/1.73 m2) by utilizing rituximab (375 mg/m2) and 
IVIG (1 g/kg/week × 4 weeks). Although serum MFI tends to decrease, there is no difference in 
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2-year graft survival between the treatment (47%) and without treatment groups (40%). These 
reports suggest a difficulty in the management for chronic changes in allografts. In addition 
to acute AMR, eculizumab was also challenged for chronic active AMR. Although there were 
no notable differences in eGFR between treatment and control groups, C1q-positive recipients 
demonstrated significant better eGFR than recipients with C1q-negative status [53]. Inhibition 
of complement-dependent allograft injury would bring benefits on certain population. Recent 
reports discussing treatment for chronic active AMR are summarized in Table 3.
In total, it is of vital importance to prevent from developing into chronic lesions and initiate 
appropriate treatment in the early stages of AMR, because fully established chronic lesions 
are irreversible. It is reasonable to believe that these managements lead to improvements of 
the long-term allograft survival.
7. Conclusion
Under the present circumstances, it is of vital importance to control AMR in advance in order 
to improve graft survival rate in all fields of organ transplantation. To detect early-stage AMR, 
clinicians need to be aware of recent advances in DSA analyses, including graft ICFA and an 
acid elution method to assess intra-graft DSA status. Preoperative desensitization therapies 
and management plans are decided depending on classes of DSA and s-DSA MFI. Conversely, 
Treatment for chronic active AMR
Author Organ Treatment Schedule Outcomes
Billing 2012 
[51]
Kidney IVIG; Rit 1 g/kg/week for 4 weeks; 
375 mg/m2 × 1
The treatment reduced or stabilized 
the progressive loss of transplant 
function in pediatric patients
Cooper 2014 
[49]
Kidney IVIG High-dose (5 g/kg) IVIG dosed 
over 6 months
No clinical treatment benefit
An 2014* 
[54]
Kidney IVIG; Rit 400 mg/kg × 4 days; 375 mg/m2 The treatment delayed CAMR 
progression
Bachelet 
2015 [50]
Kidney IVIG; Rit 1 g/kg/week for 4 weeks; 
375 mg/m2/week in the first 2 
weeks
The treatment did not seem to 
change the natural history of AMR
Redfield 
2016 [55]
Kidney Dex; IVIG; Rit (PE, 
Thymoglobulin)
100 mg of Dex; 4 weekly doses 
100 mg/kg; 375 mg/m2 body, or 
1000 mg
Better graft survival
Kulkarni 
2017 [53]
Kidney Eculizmab 600 mg/week for 4 weeks 
followed by 900 mg every 2 
weeks for a total of 26 weeks
Better eGFR in patients with C1q 
positive
Parajuli 2017 
[52]
Kidney Dex; IVIG; Rit 100 mg; 200 mg/kg/2 weeks for 
3 weeks; 375 mg/m2/week
The treatment was effective in 
reducing DSA and microcirculation 
inflammation
Ban 2017* 
[56]
Kidney IVIG; Rit 400 mg/kg × 4 days; 375 mg/m2 The treatment reduced the 
progression of CAMR
*: Reported from the same group.
Table 3. Summary of recent reports on treatments for chronic active antibody-mediated rejection (AMR).
Donor-Specific Anti-HLA Antibodies in Organ Transplantation: Transition from Serum DSA…
http://dx.doi.org/10.5772/intechopen.79846
35
even in crossmatch-negative cases, there is a possibility that memory B cells might evoke 
severe AMR 1 week following transplantation. In addition, there might be a discrepancy 
between s-DSA and g-DSA. It is also true that only relying on s-DSA MFI is difficult to deter-
mine appropriate managements. Further research is required for addressing these issues.
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